Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jeil Pharma Holdings Inc. (002620:KRX), powered by AI.
Jeil Pharma Holdings Inc. is currently trading at ₩7,350. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jeil Pharma Holdings Inc. on Alpha Lenz.
Jeil Pharma Holdings Inc.'s P/E ratio is 8.0.
“Jeil Pharma Holdings Inc. trades at a P/E of 8.0 (undervalued) with modest ROE of 4.7%.”
Ask for details →Jeil Pharma Holdings Inc. is a prominent entity in the pharmaceutical sector, recognized for its comprehensive range of healthcare products and solutions. Primarily, the company focuses on the development, manufacturing, and distribution of pharmaceuticals and medical supplies. This includes prescription medications, over-the-counter drugs, and various healthcare products that cater to a wide array of medical needs. Jeil Pharma Holdings plays a significant role in the healthcare industry by advancing medical research and enhancing public health outcomes. With its robust product portfolio, the company impacts both local and global markets by addressing critical therapeutic areas such as cardiology, neurology, and infectious diseases. The strategic position of Jeil Pharma Holdings in the market is further bolstered by its commitment to quality, innovation, and compliance with global healthcare standards. By leveraging advanced technologies and expanding its research capabilities, the company aims to contribute significantly to the progress of medical science and improve accessibility to essential healthcare products.
“Jeil Pharma Holdings Inc. trades at a P/E of 8.0 (undervalued) with modest ROE of 4.7%.”
Ask for details →Jeil Pharma Holdings Inc. (ticker: 002620) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 37 employees. Market cap is $117.4B.
The current price is ₩7,350 with a P/E ratio of 8.02x and P/B of 0.37x.
ROE is 4.68% and operating margin is 5.93%. Annual revenue is $657.6B.